As a drug development partner, we spend a lot of time talking with early-stage teams. Throughout our discussions and as we learn more about the project, two common things always seem to emerge: a desire to move fast, and Chemistry, Manufacturing, and Controls (CMC) being treated as something to address later. Of course, speed is important to development teams and investors, but when critical development decisions, such as formulation, analytical methodology, and process scalability, that determine whether a program succeeds or stalls are made without considering if they will withstand regulatory scrutiny, there is added risk that may likely delay programs by months or even years. CMC Pharmaceuticals was founded on the principle that Chemistry, Manufacturing, and Controls (CMC) is at the core of successful drug development. Every development program should have a well-developed strategy in early stages through commercialization. By putting a focus on CMC in early stages of drug development, costs are less likely to compound and timelines less likely to slip.
What is CMC and Why Does it Matter More Than Most Teams Realize?
Chemistry, Manufacturing, and Controls is the discipline that determines whether a drug can be made consistently, safely, and at scale. It’s the foundation that the whole drug development program is built on.
When the FDA receives your IND or NDA submission, the CMC section is often the first to be reviewed. Reviewers ask foundational questions, such as:
- Do we know what this drug substance and drug product are, and how they behave?
- Is the manufacturing process controlled and reproducible batch to batch?
- Are analytical methods validated and appropriate for this stage of development?
- Are specifications scientifically justified and supported by data?
- Does the container closure system protect product integrity and is there evidence to support the shelf life?
A well structured, executed, and documented development strategy enables your CMC section of your IND or NDA to answer all of those core questions clearly and defensibly. Without it, regardless of how promising the science is, the rest of your submission won’t matter.
Where Programs Fail and Why It’s So Common
CMC deficiencies are among the most common reasons for Complete Response Letters and clinical holds. In our experience, the failures are rarely the result of bad science but rather, they trace back to assumptions, planning gaps, and poor documentation.
The mistakes we see most often include:
Thinking About CMC Too Late
Formulation and manufacturing decisions are often made too early without enough regulatory consideration as to whether or not the CMC package will hold up under agency scrutiny. If decisions are made early on without thinking about how they will translate at scale, it likely means expensive rework that wasn’t in the budget and wasn’t in the timeline.
Confusing Data Generation with Submission Readiness
Running studies and generating quality data is a must, but the data must also be well organized, documented, and formatted to withstand FDA scrutiny. If it’s not, a deficiency letter will likely be issued. Building a defensible CMC package and simply generating data are not the same thing. This is why a well-thought out CMC strategy with strict execution and documentation is important to begin in early stages, not retrofitted at the end. Having regulatory foresight when designing studies is a must.
Analytical Methods that Weren’t Built to Last
This is the problem we see this most often. Analytical methods developed early in a program are often fit for purpose at the time and are not qualified or validated to the standard required for a regulatory filing. When that gap surfaces late, the timeline slips by months or years, and costs grow exponentially due to re-development, re-validation, and resubmission.
What CMC Failures Cost
Beyond a CRL or FDA deficiency letter, a CMC gap in your program can trigger a cascade effect of repeat stability studies, reformulation, re-validation, resubmission. Timelines slip and your budgets absorb costs that were never planned for.
The most expensive CMC problems we’ve seen weren’t the result of bad science, but of decisions that seemed reasonable at the time and compounded quietly until they became program-level problems. What often begins as a manageable gap, perhaps based on a cost-saving measure for early-stage feasibility studies, later becomes a filing consequence, then a rework spiral, and in some cases a program that doesn’t recover.
The difference between a delay and a failure is almost always timing and that’s why thinking about CMC activities early, with a regulatory mindset, is so critical.
What Successful CMC Strategy Looks Like
CMC programs that hold up under FDA review share one characteristic: they were designed with the reviewer’s perspective in mind from day one.
Drug development should have submission readiness built into every study, every method, and every documentation decision along the way. Stage-appropriate CMC strategy, developed in parallel with development rather than after the fact, is what separates programs that move efficiently through review from the ones that don’t.
That means:
- Integrating regulatory strategy before formulation decisions are locked in
- Building analytical methods to the standard that will be required at filing, not just at the current stage
- Generating data with documentation and submission formatting in mind from the start
- Treating every phase gate as a CMC checkpoint, not just a clinical milestone
None of this requires a perfect CMC package on day one, but it does require the right questions being asked at the right time and before the decisions that are hard to undo have already been made.
We Can Help You Get There
Whether you’re preparing for your first IND, troubleshooting a stalled program, or approaching an NDA, CMC Pharma provides integrated formulation development, analytical, and regulatory expertise to keep your program on track without the risky handoffs and knowledge gaps that derail timelines and add cost. Our Manufacturing Enablement services also include QA and QC support, helping to ensure all of the bases are covered when it comes to GMP Manufacturing.
If you’d like to pressure-test your current CMC strategy, we’re offering a complimentary 30-minute discussion to learn more about your program.
Not ready for a call? Follow CMC Pharma on LinkedIn for weekly CMC insights, practical guides, and reference content that is built for developers, investors, and program stakeholders at every stage.